findmyKOL

Himanshu Nagar, MD

Basic profile

Radiation Oncology

ORCIDNone on fileNPI↗
RegionNew York, NY · NortheastSpecialtyRadiation OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2024–2026Why? →

Himanshu Nagar is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials ↓
21companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2024–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

1275 York Ave
New York, NY 100656007

Telephone

212-639-2000

Provider last certified this registry record 30 May 2024.

View the NPPES registry record

Clinical trials

2 more trial records behind the reveal.Reveal →

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

34 more payment records behind the reveal.Reveal →
View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Genitourinary & hormones

    100%
    alpha-Adrenergic Blocker84.6%
    Tamsulosin Hcl100%
    Part D≥37 patients
    beta3-Adrenergic Agonist15.4%
    Myrbetriq100%
    Part D<11 patients
Where care is delivered (Part B)67.8% facility · 32.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”